Peripheral T-cell lymphoma (PTCL)
Conditions
Interventions
Observation group:None
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Patients who were diagnosed with peripheral T-cell lymphoma (PTCL) by histopathology from June 2026 to December 2029 and who were detected to have different molecular subtypes by next-generation sequencing (NGS) (if they were PTCL patients from January 2026 to June 2026 and had tumor tissue available for NGS testing, they were also included). 2.Fully understand and voluntarily sign the written informed consent form (ICF), willing to cooperate with the completion of genetic testing, treatment, efficacy evaluation, and long-term follow-up;
Exclusion criteria
Exclusion criteria: 1.Female patients who are pregnant, breastfeeding, or have the ability to conceive but have not taken contraceptive measures; 2.Individuals with uncontrollable neurological, mental disorders, mental disorders or cognitive impairments may limit their understanding, implementation of informed consent forms and compliance with research; 3.Other circumstances that the researchers consider unsuitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival is defined as the time from the date of randomization to the first radiological/clinical diagnosis of disease progression, recurrence (judged by the 2014 Lugano efficacy eval;Overall survival, OS;Objective response rate, ORR; | — |
Countries
China
Contacts
Public ContactWeili Zhao
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed